Trial Profile
A phase II study of bortezomib (Velcade, PS-341, IND 58443) in combination with ifosfamide/vinorelbine in pediatric patients and young adults with refractory/recurrent Hodgkin disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Filgrastim; Filgrastim; Ifosfamide; Vinorelbine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 30 Oct 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 19 Sep 2012 Status changed from completed to suspended as reported by ClinicalTrials.gov.